Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma by Muzaffar Iqbal et al.
Iqbal et al. Chemistry Central Journal 2013, 7:7
http://journal.chemistrycentral.com/content/7/1/7RESEARCH ARTICLE Open AccessDevelopment and validation of ultra-performance
liquid chromatographic method with tandem
mass spectrometry for determination of
lenalidomide in rabbit and human plasma
Muzaffar Iqbal, Tanveer A Wani*, Nasr Y Khalil and Ibrahim A DarwishAbstract
Background: Lenalidomide (LND) is a potent novel thalidomide analog which demonstrated remarkable clinical
activity in treatment of multiple myeloma disease via a multiple-pathways mechanism. Validated sensitive method
with high throughput is required for the determination of lenalidomide for pharmacokinetics and toxicokinetic
studies. Ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) is a preeminent
analytical tool for rapid biomedical analysis.
Results: A simple, highly sensitive UPLC-MS/MS method was developed and validated for the determination of LND in
rabbit and human plasma. After a simple protein precipitation using methanol, LND and carbamazepine (IS) were
separated on Acquity UPLC BEH™ C18 column (50 × 2.1 mm, i.d. 1.7 μm, Waters, USA) using a mobile phase consisted
of acetonitrile:water:formic acid (65:35:0.1%, v/v/v) pumped at a flow rate of 0.2 mL/min. LND and IS were eluted at
0.71 and 1.92 min, respectively. The mass spectrometric determination was carried out using an electrospray interface
operated in the positive mode with multiple reaction monitoring (MRM) mode. The precursor to product ion
transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively. The method was
linear in the concentration range of 0.23–1000 ng/mL with a limit of quantitation of 0.23 ng/mL. All the validation
parameters were in the ranges acceptable by the guidelines of analytical method validation.
Conclusion: The proposed UPLC-MS/MS method is simple, rapid and highly sensitive, and hence it could be reliable
for pharmacokinetic and toxicokinetic study in both animals and humans.
Keywords: Lenalidomide, Ultra performance liquid chromatography, Tandem mass spectrometry, Pharmacokinetic and
toxicokinetic, High throughput analysisBackground
Lenalidomide (LND) is an oral immunomodulatory drug
with antiangiogenic and antineoplastic properties. It struc-
turally resembles thalidomide but has an improved toxicity
profile and more potent immunomodulatory activity [1,2].
LND demonstrated remarkable clinical activity in treatment
of multiple myeloma disease [3-7] via a multiple-pathways
mechanism [8-11]. LND is rapidly absorbed with the
maximal plasma concentration occurring at a median time
of 0.6 to 1.5 hours after oral administration in healthy* Correspondence: tanykash@yahoo.co.in
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reproduction in any medium, provided the orhuman subjects. Co-administration of LND with food
delays its absorption, but it does not alter the extent of ab-
sorption. LND displays linear pharmacokinetics in healthy
subjects as well as in patients with normal renal function.
The plasma exposure of LND is dose proportional and it
does not accumulate with multiple doses. Approximately
two thirds of orally administered LND is eliminated as
unchanged in urine, likely via glomerular filtration and
active tubular secretion. The mean terminal half-life (t1/2) is
3 to 4 hours [12,13].
Many analytical methods have been reported for the
determination of LND. Two spectrophotometric [14]
and one fluorimetric [15] methods were developed forl Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Besides, two HPLC methods have been developed for
analysis of bulk material of LND and its related impurities
[16] and in capsules [17]. Two analytical reports were also
reported describing the determination of the LND in
biological samples (plasma). The first one employed liquid
chromatography-mass spectrometry using single ion moni-
toring with a limit of quantitation of 5 ng/mL[18]. The sec-
ond method included the simultaneous determination of
LND and flavopiridol by liquid chromatography-mass
spectrometry (LCMS/MS) using a single reaction monitor-
ing (SRM) and a gradient elution [19]. Both methods have
the disadvantages of long run time of 8 and 10 min
respectively which does not meet the requirement of high
throughput and speedy analysis of biosamples in clinical
laboratories. Therefore, an alternative validated method
with both high sensitivity and high throughput will be an
advance for greater efficiency in pre-clinical pharmacokin-
etics, toxicokinetic, and clinical studies.
Among the currently available bio-analytical techniques,
ultra-performance liquid chromatography (UPLC) has
gained a considerable attention in recent years and has been
emerged as the preeminent analytical tool for pharmaceutical
and biomedical analysis because of its high speed, low time
consumption, better resolution and better sensitivity. The
present study describes the development and validation of
an UPLC method coupled with tandem mass spectrometry
(UPLC-MS/MS) for the determination of LND in both
rabbit and human plasma. The method was found to be sim-
ple, highly sensitive, has high-throughput and reproducible.
Experimental
Material and method
Lenalidomide, free base (3-(4-amino-1-oxo-1,3-dihydro-
2H-isoindol-2-yl) piperidine-2,6-dione) (LC LaboratoriesW,
Woburn, MA, USA ) was obtained and used as received; its
purity was 100.2 ± 1.25%. Carmamazeipine (purity > 98%)
was obtained from Tabuk Pharmaceutical Manufacturing
Co. (Tabouk, Saudi Arabia). HPLC-grade acetonitrile and
methanol were obtained from Winlab Laboratory, UK.
Formic acid was obtained from BDH Laboratory, England.
All other reagents were of analytical grade unless stated
otherwise. All aqueous solutions were prepared using water
that was purified using Milli-QR Gradient A10R (Millipore,
Moscheim Cedex, France) having pore size 0.22 μm.
Apparatus and operating condition
Liquid chromatography
The chromatography was performed on an ACQUITY ™
UPLC system (Waters Corp., Milford, MA, USA). The
UPLC system included quaternary solvent manager, a
binary pump, degasser, autosampler with an injection
loop of 10 μL and a column heater-cooler. The separation
was performed on Acquity UPLC BEH™ C18 column(50 × 2.1 mm, i.d., 1.7 μm, Waters, USA) maintained at
45°C. The mobile phase was composed of acetonitrile:
water:formic acid (65:35:0.1%, v/v/v) at a flow rate of
0.2 mL/min. The injection volume was 5 μL in partial
loop mode and the temperature of the autosampler was
kept at 4°C.
Mass spectrometric conditions
A triple-quadrupole tandem mass spectrometer (Micro-
massW Quattro micro™ Waters Corp., Milford, MA, USA)
equipped with electrospray ionization (ESI) interface was
used for analytical detection. The ESI source was operated
in positive ionization mode. Quantification was performed
using multiple reaction monitoring (MRM) of the transi-
tions of m/z 260.1 > 149.0 for LND and m/z 237.0 > 179.0
for carbamazepine, with the dwell time of 0.16 s. Nitrogen
was used as a desolvating gas at a flow rate of 600 L/h. The
desolvating temperature was 350°C whereas source
temperature was 150°C. The collision gas (argon) flow was
0.1 mL/min and capillary voltage was set at 4 kV. The MS
analyzer parameters were as follows: LM1 and HM1
resolution 14.0 and 14 respectively; ion energy 1; LM2 and
HM2 resolution 10.0 and 14.0 respectively, ion energy 2.
The compound parameters like cone voltage and collision
energy were optimized and set at 27 V and 19 eV for LND
and 36 V and 36 eV for IS respectively. The Mass Lynx
software (Version 4.1, SCN 714) was used to control the
UPLC-MS/MS system and data was collected and
processed using TargetLynx™ program.
Calibration standards and quality control samples
A standard stock solution of LND and carbamazepine
internal standard (IS) were prepared by dissolving the com-
pound in dimethylsulphoxide and methanol, respectively
to give a final concentrations of 1 mg/mL. The solutions
were kept in the refrigerator and could be used for 15 days
from the date of preparation. Stock solution of LND was
used for calibration standards and quality control (QC)
samples, respectively. Working solutions of LND were
prepared in methanol:water (50:50, v/v) to obtain aqueous
calibration curve standards of 11.52-50000 ng/mL. A 20
μL aliquot of each working solution was added to blank
human/rabbit plasma to yield calibration standards ranging
from 0.23 to 1000 ng/mL. QC samples at four different
concentrations (0.26, 1.28, 64 and 800 ng/mL) were pre-
pared in a similar manner as the calibration standards
and they are treated as LLOQ QC, LQC, MQC and
HQC respectively. Spiked plasma calibration standards
and quality control samples were kept at −80°C until
assayed or used for validating the assay procedures.
The IS working solution (5 μg/mL) for routine use was
prepared by diluting the carbamazepine stock solution
in methanol:water (50:50, v/v) and kept at room
temperature (25 ± 2°C).
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Plasma samples stored at around −80°C were thawed,
left for 1 hour and vortex for 30 sec on room
temperature before extraction to ensure homogeneity.
To 200 μL of plasma sample 20 μL of working standard
and 25 μL (5 μg/mL) of IS (except blank sample) was
added. The samples were vortex mixed for about 30 sec
and 750 μL of methanol was added to it. The samples
were again vortex mixed gently for 1.5 min and then
cold centrifuged for 10 min at 10000 rpm. After centri-
fugation, 400 μl of supernatant was transferred into
HPLC vial, and 5 μL volumes (in partial loop with needle
over fill mode) of the sample were subjected to the ana-
lysis by UPLC–MS/MS.
Method validation
A full method validation was performed according to
guidelines set by the United States Food and Drug
Administration (US-FDA) and European Medicines
Agency (EMEA) guidelines [20,21]. The validation of
this procedure was performed in rabbit plasma in order
to evaluate the method in terms of selectivity, linearity
of response, accuracy, precision, recovery, dilution integrity
and stability of analytes during both short-term sample
processing and long-term storage. Selectivity, linearity,
accuracy and precision exercise was also performed in
human plasma.
Selectivity and specificity
The selectivity of the method towards endogenous plasma
matrix components, metabolites and component medica-
tions was assessed in rabbit and human blank plasma.
Among the analyzed batch, plasma batch showing no or
minimal interference at the retention time of analyte and
internal standard was selected. They were processed and
analyzed using the proposed extraction protocol spiked
with standard LND at LLOQ level (0.23 ng/mL) and
carbamazepine (IS) at 100 ng/mL level.
Linearity and standard curve
The linearity of the method was determined by analysis of
standard plots associated with an eight point standard
calibration curve (0.23-1000 ng/mL). Calibration curves
from accepted three precision and accuracy batches were
used to establish linearity. Curves were best fitted using a
least square linear regression model y = mx + b, weighted
by 1/x2, in which y is the peak area ratio, m is slope of the
calibration curve, b is the y-axis intercept of the calibration
curve and x is the analyte (LND) concentration. Back-
calculations were made from these curves to determine the
concentration of LND in each calibration standards and
the resulting calculated parameters were used to determine
concentrations of analyte in quality control samples. The
determination coefficient r2 > 0.98 was desirable for all thecalibration curves. The lowest standard on the calibration
curve was to be accepted as the lower limit of quantifica-
tion (LLOQ), if the analyte response was at least five times
more than that of drug free (blank) extracted plasma. In
addition, the analyte peak of LLOQ sample should be
identifiable, discrete, and reproducible with accuracy
within ± 20% and a precision ≤ 20%. The deviation of stan-
dards other than LLOQ from the nominal concentration
should not be more than ± 15.0%.
Precision and accuracy
Intra- and inter-day accuracies expressed as a percentage
of deviation from the respective nominal value. The
precision of the assay was measured by the percent
coefficient of variation (% CV) at four concentrations
in both rabbit and human plasma. Intra-day precision
and accuracy were assessed by analyzing six replicates
of the quality control samples at four levels (quality
control) during a single analytical run. The inter-day
precision and accuracy were assessed by analyzing 18
replicates of the quality control samples at each level
through three precision and accuracy batches runs on
2 consecutive validation days. The deviation at each
concentration level from the nominal concentration
was expected to be within ±15.0% except LLOQ QC,
for which it should not be more than 20.0%. Simi-
larly, the mean accuracy should not deviate by ±
15.0% except for the LLOQ QC where it can be ±
20.0% of the nominal concentration.
Extraction recovery and matrix effect
Standard aqueous quality control stock of LND each at
low, medium, and high concentration levels were spiked
in plasma and millipore water separately, the later being
considered as unextracted QC samples. Six replicates of
each QC plasma samples were processed as usual and
analyzed along with six replicates of unextracted stand-
ard QC samples by applying correction factor to nullify
dilution of extracted samples during plasma processing.
Six replicates of aqueous carbamazepine were also run
for the recovery of carbamazepine.
Stability and dilution integrity evaluation
Stability of LND in plasma was assessed by analyzing six
replicates of QC samples at low and high concentrations
under a variety of storage and processing conditions. Six
aliquots of each low and high concentration quality control
samples were taken to evaluate the bench top stability
(short term stability), freeze thaw stability, autosampler
storage stability and long term stability. Bench-top stability
was assessed after exposure of the plasma samples to room
temperature for ∼ 6 h, which exceeds the residence
time of the sample processing procedures. The freeze–












Figure 1 Chemical structure of lenalidomide [A] and carbamazepine (IS) [B].
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The autosampler storage stability was determined by stor-
ing the reconstituted QC samples for ∼ 48 h under auto-
sampler condition (maintained at 8°C) before being
analyzed. Long-term stability was assessed after storage of
the test samples at around −80°C for 30 days. The working
solutions and stock solutions of LND and the IS were also
evaluated for stability at room temperature for 12 h and atFigure 2 The product ion spectra of lenalidomide [A] and carbamazerefrigerator temperature (below 10°C) for 15 days. All sta-
bility exercises were performed against freshly spiked cali-
bration standards. The samples were considered stable in
plasma at each concentration if the deviation from the
mean calculated concentration of stability quality control
samples was within ±15%.
Dilution integrity exercise was carried out to ensure
the integrity of analyte in those samples which arepine (IS) [B].
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diluted. A fresh stock of LND was prepared and spiked
in plasma to get a conc. level of 1.8 times of highest
standard of the usual calibration standard. It was then
diluted 2 times and 4 times with the same plasma. Six
aliquots of both dilutions were processed along with
freshly spiked calibration standards and analyzed by back
calculation using regression equation obtained. The
integrity of the samples were considered to be maintained
if -% nominal is within ± 15% of nominal values and %
CVs ≤ 15% at both diluted levels.
Result and discussion
Optimization of chromatographic condition
Initial feasibility experiments of various mixture(s) of
organic solvents such as acetonitrile and methanol along
with pure water; both having 0.1% formic acid along with
altered flow-rates (in the range of 0.20–0.4 mL/min) was
performed to optimize an effective chromatographic reso-
lution of LND and IS; their chemical structures are given
in Figure 1. The best resolution of peaks were achieved
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Figure 3 Representative chromatograms of blank [A] and LLOQ [B] ofacetonitrile:water:formic acid (65:35:0.1%, v/v/v) at a flow-
rate of 0.2 mL/min, on Acquity UPLC BEH™ C18 column
(50 × 2.1 mm, i.d. 1.7 μm). The selected conditions were
found to be suitable for the determination of electrospray
response for LND and IS.
UPLC-MS/MS operation parameters were carefully
optimized for the determination of LND. Both analyte
and IS were detected by tandem mass spectrometry
using MRM of precursor–product ion transitions with
0.160 s dwell time, at m/z 260.1 > 149.0 for LND and m/z
237.0 > 179.0 for carbamazepine. A standard solution
(100 ng/mL) of LND and the carbamazepine were directly
infused along with the mobile phase into the mass
spectrometer with ESI as the ionization source. The mass
spectrometer was tuned initially in both positive and
negative ionization modes for LND. It was observed that
the signal intensity of positive ion was much higher than
that of negative ion. Parameters, such as capillary and
cone voltage, desolvation temperature, ESI source
temperature and flow rate of desolvation gas and cone
gas, were optimized to obtain the optimum intensity of
deprotonated molecules of LND and IS for quantification.min
1.60 1.80 2.00 2.20 2.40 2.60
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LND in rabbit plasma.
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especially cone voltage, were important parameters. The
precursor ion intensities increased significantly when cone
voltage was raised gradually. Lastly, analytes produced the
strongest ion signals when cone voltage was set up at
27 V. While cone voltage exceeded 27 V, the ion signals
decreased rapidly. The collision energy was investigated
from 10 to 50 eV to optimize the response of product ion,
and the best values were found to be 19 eV for the chosen
product ions (m/z 149). For IS, although the most abundant
fragment ion was observed at m/z 191.0, but m/z spectra at
179.0 at the optimum collision energy 36 eV give more
resolved peak hence chosen for quantification. The product
ion spectra of LND and IS were shown in Figure 2.
Optimization of sample processing
Protein precipitation was used for sample preparation in
this study. Protein precipitation can be helpful in produ-
cing a clean sample and avoiding endogenous substances
in plasma with the analytes and IS onto the column and
MS system. Clean samples are essential for minimizing
ion suppression and matrix effect in UPLC–MS/MS
analysis. Two organic solvents: methanol and acetonitrile
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Figure 4 Representative chromatograms of carbamazepine (IS) in blaFinally methanol was found to be optimal, which can
produce a clean chromatogram for a blank plasma
sample and yield the highest recovery for the analytes
from the rabbit plasma.
Selectivity
Selectivity of the method was assessed by comparing
the chromatograms of both rabbit and human blank
plasma with the corresponding spiked LLOQ sample.
Only those lots which are under the acceptance criteria
(< 20% in comparison to the spiked LLOQ and < 5% in
comparison to IS area) were selected. This infers that
there were no potential significant endogenous
substances in plasma that interfered with the peaks of
analyte and IS. Thus the method looks to be selective
enough for determination of LND and carbamazepine
in plasma. Representative chromatograms obtained
from blank plasma showing no interference at the
retention time of analyte and IS are shown in Figures 3
[A] and 4 [A], respectively. Representative chromato-
gram of LLOQ and IS are shown in Figures 3 [B] and 4
[B], respectively whereas representative chromatogram
of LQC and HQC are shown in Figure 5 [A] and [B]
respectively.min
min
1.60 1.80 2.00 2.20 2.40 2.60 2.80
1.60 1.80 2.00 2.20 2.40 2.60 2.80
F1:MRM of 1 channel,ES+
260.1 > 149
4.600e+003
nk [A] and HQC [B] in rabbit plasma.
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The linearity of the method was determined by a
weighted least square regression analysis of standard
plot associated with an eight-point standard curve. The
calibration curves were generated by plotting area ratio
(LND/IS) as a function of LND concentration. It was
found to be linear from 0.23 to 1000 ng/mL for LND in
both rabbit and human plasma. The determination coef-
ficients (r2) were consistently greater than 0.995 during
the course of validation. The lower limit of quantification
for this assay was 0.23 ng/mL in plasma. Representative
LLOQ is sensitive enough to investigate the pharmacoki-
netic behavior of LND in both rabbit and human.
Precision and accuracy
Table 1 summarizes the inter- and intra-day precision


































Figure 5 Representative chromatograms of LQC [A] and HQC [B] of LNvariation values of both intra- and inter-day results of
rabbit plasma were 2.14 - 12.2 and 4.62 - 9.67%, respect-
ively, whereas the intra- and inter-day accuracies were
91.4–108 and 95.1 – 104%, respectively. Similarly coeffi-
cients of variation values of both intra- and inter-day
results were 1.97 - 9.61 and 4.54-9.72% respectively
whereas intra- and inter-day accuracies were 93.5–113%
and 98.3 – 111%, respectively in human plasma. These
results indicate that the method has good precision and
accuracy and are within the acceptance limit of < 15%
and ± < 15% for precision and accuracy respectively.
Recovery
Table 2 summarizes the percentage recovery of LND
and carbamazepine (IS). The percentage recoveries
(mean ± SD) of LND obtained from plasma at three QC
concentration levels (1.28, 64 and 800 ng/mL), weremin
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.60 1.80 2.00 2.20 2.40 2.60 2.80




















D in rabbit plasma.
Table 1 Intra- and inter-day precision and accuracy of LND in rabbit and human plasma













Intraday variation (six replicate at each concentration)
0.26 1 0.27 ± 0.02 6.98 103 0.29 ± 0.01 3.60 110
2 0.26 ± 0.03 9.51 101 0.29 ± 0.03 9.61 109
3 0.28 ± 0.03 12.2 108 0.30 ± 0.03 9.53 113
1.28 1 1.30 ± 0.07 6.74 101 1.32 ± 0.08 5.80 103
2 1.32 ± 0.04 3.09 103 1.34 ± 0.05 3.51 105
3 1.36 ± 0.06 4.78 106 1.37 ± 0.06 4.16 107
64.0 1 59.3 ± 5.35 9.02 92.7 59.8 ± 5.95 9.94 93.5
2 64.8 ± 4.26 6.57 101 64.8 ± 5.42 8.36 101
3 58.5 ± 6.19 10.60 91.4 63.8 ± 5.91 9.26 99.7
800 1 832 ± 17.70 2.14 104 814 ± 43.60 5.36 102
2 778 ± 19.30 2.48 97.2 790 ± 34.50 4.37 98.8
3 775.8 ± 38.60 4.97 97.0 769 ± 15.10 1.97 96.1
Intraday variation (18 replicates at each concentration)
0.26 0.27 ± 0.03 9.67 104 0.29 ± 0.03 9.72 111
1.28 1.32 ± 0.06 4.80 103 1.34 ± 0.06 4.54 105
64 60.9 ±5.80 9.49 95.1 62.9 ± 5.91 9.40 98.3
800 795 ±36.80 4.62 99.4 791 ± 36.60 4.62 99.2












1.28 1.32 ± 0.08 6.13 103
800 753 ± 26.24 3.50 94.1
Freeze thaw
(3 cycle)
1.28 1.33 ± 0.05 3.77 104
800 767 ± 23.76 3.10 95.8
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mean recovery for the carbamazepine (IS) at the con-
centration employed was 75.5 ±7.6%. This result indi-
cates that the extraction efficiency for LND using
protein precipitation method was satisfactory, consist-
ent and concentration independent.
Stability and dilution integrity
The stabilities of LND were investigated at two concen-
trations of QC samples (low and high concentrations) to
cover expected conditions during analysis, storage and
processing of all samples, which include the stability
data from various stability exercises like in-injector,
bench-top, freeze/thaw and long-term stability tests. The
stability results summarized in Table 3 indicate that
LND spiked into rabbit plasma was stable for at least
6.0 h at room temperature, for at least 48 h in final
extract at 8°C under autosampler storage condition, forTable 2 Recovery data of LND (three QC samples) and
carbamazepine in rabbit plasma
Compound Nominal conc. (ng/mL) Recovery (% ± SD )
LND (analyte) 1.28 71.4 ± 7.9
64 70.5 ± 6.4
800 72.5 ± 8.0
Mean ± SD 71.4 ± 0.8
Carbamazepine (IS) 100 75.5 ±7.630 days at around −80°C, and during three freeze–thaw
cycles when stored at around −80°C and thawed to room
temperature. These results indicate that there is no
significant degradation of LND under the storage or
handling conditions evaluated. The stock solutions and
working standard of LND and IS were also stable for
15 days at refrigerator temperature (below 10°C) and forIn injector
(48 h)
1.28 1.32 ± 0.06 4.24 103
800 787 ± 38.06 4.80 98.3
30 days
at ̶ 80°C
1.28 1.35 ± 0.04 2.79 105
800 752 ± 16.24 2.16 94
Dilution
integrity
360 373 ± 24.80 6.60 104
720 681 ± 28.90 4.20 94.6
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to be stable upto 30 days at −80°C in spiked plasma and
up to 15 days in aqueous solution in refrigerator, as
reported previously [19].
In dilution integrity study, the% accuracy of two and
four times diluted sample was to 94.6 and 103.6% of the
nominal concentration for LND. These results conclude
that the dilution of the concentrated plasma sample upto
four times maintains legibility and integrity of LND
concentration.
Advantages of the proposed method over the reported
methods
This study represents the first report describing the
determination of LND in both animal and human
plasma by UPLC-MS/MS method. The proposed method
is superior to the previously reported LC-MS methods in
terms of the sensitivity and simplicity as the method
described herein is based on simple one step protein
precipitation for sample preparation and isocratic flow of
mobile phase containing acetonitrile:water:formic acid
(65:35:0.1%, v/v/v) at a flow rate of 0.2 mL/min only. The
run time was only 2.5 min which is suitable for high-
throughput analysis.
Conclusions
A novel simple, economical high-throughput and highly
sensitive UPLC-MS/MS method was successfully devel-
oped and validated for the determination of LND in
rabbit and human plasma. The method involved simple
one step protein precipitation method for plasma sample
preparation and short runtime (2.5 min) for analysis.
The proposed method could be practical and reliable for
pharmacokinetic and toxicokinetic study for LND in
both animal and human.
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